BRAF and melanoma: Subsequently, the BRAF inhibitors PLX4032 (vemurafenib) and GSK2118436 (dabrafenib) were synthesized and used in the clinical treatment of BRAF mutation melanoma [84,85,101,102,103] (Figure 4).